Teknova Announces Pricing of $40 Million Public Offering of Common Stock

Impact · against what's priced in

TKNO is facing immediate equity dilution through the issuance of 8 million shares. While the $40 million cash infusion strengthens the balance sheet, the dilution to shareholders is the primary driver of the short-term price impact.

TKNO−0.30: No priced-in read yet
In context: The pricing of 8 million shares at $5.00 per share creates direct equity dilution, which outweighs the benefit of the $40 million gross proceeds.
Read from the article alone

Teknova Announces Pricing of $40 Million Public Offering of Common Stock

biotech▲5%
TKNO
capital raise
diagnostics
equity issue
public offering
reagents
vaccines

Top 1 mover · tap to explore

Teknova Announces Pricing of $40 Million Public Offering of Common Stock

What matters in this story

REGENXBIO Inc. (RGNX) Discusses Clinical Program Progress and Commercial Outlook in Wet AMD and Rare Diseases Transcript

Teknova Announces Pricing of $40 Million Public Offering of Common Stock

What matters in this story

REGENXBIO Inc. (RGNX) Discusses Clinical Program Progress and Commercial Outlook in Wet AMD and Rare Diseases Transcript

How each ticker is affected

Track these names every morning.

Innate Pharma to Participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference

Beta Bionics, Inc. Notice of November 3, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

vTv Therapeutics Inc. (VTVT) Discusses Hypoglycemia Burden in Type 1 Diabetes and Cadisegliatin Phase 3 Program Transcript

Actinogen Medical enters ‘database lock' to process XanaMIA' data and confirm findings

Teknova Announces Pricing of $40 Million Public Offering of Common Stock

What matters in this story

Next reads from the same story arc

REGENXBIO Inc. (RGNX) Discusses Clinical Program Progress and Commercial Outlook in Wet AMD and Rare Diseases Transcript

Teknova Announces Pricing of $40 Million Public Offering of Common Stock

What matters in this story

Next reads from the same story arc

REGENXBIO Inc. (RGNX) Discusses Clinical Program Progress and Commercial Outlook in Wet AMD and Rare Diseases Transcript

How each ticker is affected

Track these names every morning.

Innate Pharma to Participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference

Beta Bionics, Inc. Notice of November 3, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

vTv Therapeutics Inc. (VTVT) Discusses Hypoglycemia Burden in Type 1 Diabetes and Cadisegliatin Phase 3 Program Transcript

Actinogen Medical enters ‘database lock' to process XanaMIA' data and confirm findings